Oral and Gut Microbiota for Differentiating Benign Pulmonary Nodules from Lung Cancer

111 participants provided saliva and fecal samples for a study investigating microbial biomarkers for lung cancer. The dataset includes 16S rRNA gene sequencing results from healthy controls, individuals with benign nodules, and early- and advanced-stage lung cancer patients. Results indicate salivary Rothia mucilaginosa and gut Bacteroides coprocola as promising diagnostic markers.

Use Cases

• Training a classifier to distinguish benign pulmonary nodules from lung cancer based on microbial abundance data.
• Identifying stage-specific microbial signatures for lung cancer progression using trend analysis across patient groups.
• Evaluating the diagnostic efficacy of candidate biomarkers like Rothia mucilaginosa via ROC curve analysis.

Strengths

• Includes data from 111 participants across four distinct clinical groups, enabling comparative analysis.
• Focuses on distinguishing tumor-specific alterations by incorporating a critical control group of 18 individuals with benign nodules.
• Reports specific diagnostic performance metrics, such as an AUC of 0.901 for gut Bacteroides coprocola.

Limitations

• Row count is unknown, which may limit suitability assessment.
• Column-level documentation is absent; field semantics must be inferred after download.
• The dataset is very small at 15.3 KB, indicating limited scope.

Provenance

Source

figshare

Collection Method

16S rRNA gene sequencing (V3-V4 region) of saliva and fecal samples from a retrospective case-control study.

Freshness

Last updated 2026-05-19 05:38:44; freshness should be verified.